| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Jose M Rubio, Christoph U Correl. Clozapine and long-acting injectable antipsychotics reduce hospitalisation and treatment failure risk in patients with schizophrenia. Evidence-based mental health. vol 21. issue 3. 2019-05-17. PMID:29997153. |
clozapine and long-acting injectable antipsychotics reduce hospitalisation and treatment failure risk in patients with schizophrenia. |
2019-05-17 |
2023-08-13 |
Not clear |
| Dalia Ismail, Karawen Tounsi, Monica Zolezzi, Yassin Eltork. A qualitative exploration of clozapine prescribing and monitoring practices in the Arabian Gulf countries. Asian journal of psychiatry. vol 39. 2019-05-08. PMID:30597443. |
clozapine is considered as the first line antipsychotic for treatment resistant schizophrenia (trs). |
2019-05-08 |
2023-08-13 |
human |
| Jan P A M Bogers, Peter F J Schulte, Theo G Broekman, Peter Moleman, Lieuwe de Haa. Dose reduction of high-dose first-generation antipsychotics or switch to ziprasidone in long-stay patients with schizophrenia: A 1-year double-blind randomized clinical trial. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 28. issue 9. 2019-05-03. PMID:30025751. |
neither fga dose reduction nor switching to ziprasidone is an adequate alternative to clozapine for long-stay patients with severe treatment resistant schizophrenia. |
2019-05-03 |
2023-08-13 |
Not clear |
| Vincenzo Prisco, Petrosino Monica, Germano Fiore, Annamaria Tridente, Antonietta La Rocca, Francesco Catapano, Michele Fabrazz. Brain Natriuretic Peptide as a Biomarker of Asymptomatic Clozapine-Related Heart Dysfunction: A Criterion for a More Cautious Administration. Clinical schizophrenia & related psychoses. vol 12. issue 4. 2019-04-29. PMID:27996318. |
we reported the clinical cases of two women, aged 22 and 28 years, affected by schizophrenia with pericarditis symptoms related to clozapine treatment of 200 mg/day. |
2019-04-29 |
2023-08-13 |
human |
| Katlyn L Nemani, M Claire Greene, Melissa Ulloa, Brenda Vincenzi, Paul M Copeland, Sulaiman Al-Khadari, David C Henderso. Clozapine, Diabetes Mellitus, Cardiovascular Risk and Mortality: Results of a 21-Year Naturalistic Study in Patients with Schizophrenia and Schizoaffective Disorder. Clinical schizophrenia & related psychoses. vol 12. issue 4. 2019-04-29. PMID:29164928. |
clozapine, diabetes mellitus, cardiovascular risk and mortality: results of a 21-year naturalistic study in patients with schizophrenia and schizoaffective disorder. |
2019-04-29 |
2023-08-13 |
Not clear |
| Radhika Sudhir Joshi, Shishu Pal Singh, Mitradas M Panicke. 5-HT Journal of pharmacological sciences. vol 139. issue 2. 2019-04-17. PMID:30600145. |
5-ht clozapine is an antipsychotic known for its superior efficacy in treating drug-resistant schizophrenia. |
2019-04-17 |
2023-08-13 |
Not clear |
| Takayuki Furuishi, Kohei Sekino, Mihoko Gunji, Kaori Fukuzawa, Hiromasa Nagase, Tomohiro Endo, Haruhisa Ueda, Etsuo Yonemoch. Effect of sulfobutyl ether-β-cyclodextrin and propylene glycol alginate on the solubility of clozapine. Pharmaceutical development and technology. vol 24. issue 4. 2019-04-15. PMID:30126299. |
clozapine (clz) is an atypical antipsychotic medication used in the treatment of schizophrenia and is poorly soluble in water (0.05 mm). |
2019-04-15 |
2023-08-13 |
Not clear |
| Lisanne M Geers, Dan Cohen, Laura M Wehkamp, Kai van Hateren, Remco A Koster, Olga Yu Fedorenko, Arkadyi V Semke, Nikolay Bokhan, Svetlana A Ivanova, Jos G W Kosterink, Anton J M Loonen, Daan J Tou. Dried Blood Spot Analysis for Therapeutic Drug Monitoring of Clozapine. The Journal of clinical psychiatry. vol 78. issue 9. 2019-04-03. PMID:29068609. |
clozapine is an antipsychotic drug that is mainly used in the treatment of schizophrenia patients who are refractory or intolerant to at least 2 other antipsychotics. |
2019-04-03 |
2023-08-13 |
Not clear |
| Carolyn Beth McNabb, Frederick Sundram, Ian Soosay, Robert R Kydd, Bruce Roy Russel. Increased sensorimotor network connectivity associated with clozapine eligibility in people with schizophrenia. Psychiatry research. Neuroimaging. vol 275. 2019-04-01. PMID:29650266. |
increased sensorimotor network connectivity associated with clozapine eligibility in people with schizophrenia. |
2019-04-01 |
2023-08-13 |
Not clear |
| Carolyn Beth McNabb, Frederick Sundram, Ian Soosay, Robert R Kydd, Bruce Roy Russel. Increased sensorimotor network connectivity associated with clozapine eligibility in people with schizophrenia. Psychiatry research. Neuroimaging. vol 275. 2019-04-01. PMID:29650266. |
these data reveal differences in functional connectivity between flr and those eligible for clozapine and suggest that greater connectivity between the smn and precuneus may be indicative of treatment resistance in people with schizophrenia. |
2019-04-01 |
2023-08-13 |
Not clear |
| Mario de la Fuente Revenga, Daisuke Ibi, Justin M Saunders, Travis Cuddy, Maryum K Ijaz, Rudy Toneatti, Mitsumasa Kurita, Terrell Holloway, Li Shen, Jeremy Seto, Mikhail G Dozmorov, Javier González-Maes. HDAC2-dependent Antipsychotic-like Effects of Chronic Treatment with the HDAC Inhibitor SAHA in Mice. Neuroscience. vol 388. 2019-03-29. PMID:30025863. |
antipsychotic drugs, including both typical such as haloperidol and atypical such as clozapine, remain the current standard for schizophrenia treatment. |
2019-03-29 |
2023-08-13 |
mouse |
| Parita Shah, Yusuke Iwata, Eric Plitman, Eric E Brown, Fernando Caravaggio, Julia Kim, Shinichiro Nakajima, Margaret Hahn, Gary Remington, Philip Gerretsen, Ariel Graff-Guerrer. The impact of delay in clozapine initiation on treatment outcomes in patients with treatment-resistant schizophrenia: A systematic review. Psychiatry research. vol 268. 2019-03-26. PMID:30015109. |
the impact of delay in clozapine initiation on treatment outcomes in patients with treatment-resistant schizophrenia: a systematic review. |
2019-03-26 |
2023-08-13 |
Not clear |
| Parita Shah, Yusuke Iwata, Eric Plitman, Eric E Brown, Fernando Caravaggio, Julia Kim, Shinichiro Nakajima, Margaret Hahn, Gary Remington, Philip Gerretsen, Ariel Graff-Guerrer. The impact of delay in clozapine initiation on treatment outcomes in patients with treatment-resistant schizophrenia: A systematic review. Psychiatry research. vol 268. 2019-03-26. PMID:30015109. |
approximately one-third of patients with schizophrenia have treatment-resistant schizophrenia (tr-scz), which is a condition characterized by suboptimal response to antipsychotics other than clozapine. |
2019-03-26 |
2023-08-13 |
Not clear |
| Heidi Taipale, Juha Mehtälä, Antti Tanskanen, Jari Tiihone. Comparative Effectiveness of Antipsychotic Drugs for Rehospitalization in Schizophrenia-A Nationwide Study With 20-Year Follow-up. Schizophrenia bulletin. vol 44. issue 6. 2019-03-19. PMID:29272458. |
clozapine and lais are the most effective treatments in preventing psychiatric and all-cause hospitalization among chronic and first-episode patients with schizophrenia. |
2019-03-19 |
2023-08-13 |
Not clear |
| H C van Mierlo, C D Schubart, N M S Golüke, K M Bessembinders, J K Tijdin. [Acute dystonia in a patient with an elevated clozapine level due to an infection]. Tijdschrift voor psychiatrie. vol 60. issue 12. 2019-03-18. PMID:30536298. |
we describe the case of a 75-year-old patient with late-onset schizophrenia who used clozapine. |
2019-03-18 |
2023-08-13 |
Not clear |
| Ryo Okubo, Naoki Hashimoto, Mami Kusachi, Hisashi Narita, Ichiro Kusum. [A Case of Dilated Cardiomyopathy after 17 Years of Clozapine Treatment]. Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica. vol 118. issue 10. 2019-03-15. PMID:30620827. |
a 43-year-old male with a 24-year history of schizophrenia was treated with clozapine (600 mg/day) for 17 years. |
2019-03-15 |
2023-08-13 |
Not clear |
| Samantha A Hollingworth, Karl Winckel, Nargess Saiepour, Amanda J Wheeler, Nicholas Myles, Dan Siskin. Clozapine-related neutropenia, myocarditis and cardiomyopathy adverse event reports in Australia 1993-2014. Psychopharmacology. vol 235. issue 7. 2019-03-13. PMID:29589067. |
clozapine is the gold-standard medicine for treating refractory schizophrenia but there are some notable serious adverse events (ae). |
2019-03-13 |
2023-08-13 |
Not clear |
| Oddur Ingimarsson, James H MacCabe, Engilbert Sigurdsso. Constipation, ileus and medication use during clozapine treatment in patients with schizophrenia in Iceland. Nordic journal of psychiatry. vol 72. issue 7. 2019-03-13. PMID:30348045. |
constipation, ileus and medication use during clozapine treatment in patients with schizophrenia in iceland. |
2019-03-13 |
2023-08-13 |
Not clear |
| Oddur Ingimarsson, James H MacCabe, Engilbert Sigurdsso. Constipation, ileus and medication use during clozapine treatment in patients with schizophrenia in Iceland. Nordic journal of psychiatry. vol 72. issue 7. 2019-03-13. PMID:30348045. |
purpose of the article: clozapine is the only evidence based treatment for treatment-resistant schizophrenia. |
2019-03-13 |
2023-08-13 |
Not clear |
| Oddur Ingimarsson, James H MacCabe, Engilbert Sigurdsso. Constipation, ileus and medication use during clozapine treatment in patients with schizophrenia in Iceland. Nordic journal of psychiatry. vol 72. issue 7. 2019-03-13. PMID:30348045. |
the aims of this study are to describe the prevalence of constipation and ileus during clozapine treatment of patients with schizophrenia in iceland and to assess the concomitant use of medication that can cause constipation, and laxatives used to treat constipation. |
2019-03-13 |
2023-08-13 |
Not clear |